STOCKHOLM, SWEDEN--(Marketwire - May 31, 2012) - Birgitte Volck has been appointed Senior
Vice President, Chief Medical Officer
at Sobi with responsibility for Clinical Development, Regulatory Affairs,
Drug
Safety and Medical Affairs.
Birgitte Volck is currently Executive Development Director, Bone,
Neuroscience &
Inflammation at Amgen Limited in Uxbridge, UK. She has held several senior
positions within Amgen since 2007, including Executive Medical Director,
Nordic
& Baltic Region. Prior to Amgen she was Nordic Medical Director & Project
Director at Genzyme A/S in Denmark 2004-2007, and Vice President, Clinical
Development & Medical Affairs at Pharmexa A/S in Denmark 2001-2004.
During 1991-2000 she had various clinical and scientific assignments,
mainly
within rheumatology, at the Copenhagen University Hospitals. She holds a
PhD and
has published a number of scientific papers related to inflammation,
connective
tissue metabolism, biomarkers and arthritis.
Birgitte Volck, 49 years, is MD and PhD from the University of Copenhagen.
She
will report to CEO Geoffrey McDonough and will be a member of the Executive
Leadership Team. She will assume her position on
August 1, 2012.
"We are delighted to welcome Birgitte to Sobi. With her extensive
experience in
drug development and integrated and patient focused Medical Affairs,
Birgitte
will bring a perspective and drive to our medical organization as we
advance our
life cycle management and late stage pipeline projects," says Geoffrey
McDonough, CEO of Sobi.
Swedish Orphan Biovitrum (Sobi)
Sobi is a leading integrated biopharmaceutical company dedicated to
bringing
innovative therapies and services to improve the health of rare disease
patients
and their families. The product portfolio comprises about 45 marketed
products
as well as projects in the late clinical phase. Key therapeutic areas are
Inflammation and Genetics & Metabolism. In 2011, Sobi had revenues of SEK
1.9
billion and around 500 employees. The share (STO: SOBI) is listed on NASDAQ
OMX
Stockholm. More information is available at www.sobi.com.
The information above has been published pursuant to the Swedish Securities
Market Act and/or the Financial Instruments Trading Act. The information
was
released for public distribution on 31 May 2012 at 08.30 CET.
Sobi press release May 31, 2012 in pdf format:
http://hugin.info/134557/R/1616170/515367.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Swedish Orphan Biovitrum AB (publ) via Thomson Reuters ONE
[HUG#1616170]
